A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

• Status: Completed
• Trial end date: 2021-03-29
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ferring Pharmaceuticals
• Collaborators: Duke Clinical Research Institute; Memorial Sloan Kettering Cancer Center
• Treatments: Leuprolide

Criteria

Inclusion Criteria:

• Advanced prostate cancer

• Indication to initiate androgen deprivation therapy (ADT)

• Predefined cardiovascular disease

Exclusion Criteria:

• Previous or current hormonal management of prostate cancer (unless terminated at least 12 months prior to trial)

• Acute cardiovascular disease in the previous 30 days